CG Oncology Common stock Statistics
Share Statistics
CG Oncology Common stock has 76.13M shares outstanding. The number of shares has increased by 14.25% in one year.
| Shares Outstanding | 76.13M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 13.5% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 47.40M |
| Failed to Deliver (FTD) Shares | 20.50K |
| FTD / Avg. Volume | 3.34% |
Short Selling Information
The latest short interest is 4.99M, so 6.55% of the outstanding shares have been sold short.
| Short Interest | 4.99M |
| Short % of Shares Out | 6.55% |
| Short % of Float | 10.52% |
| Short Ratio (days to cover) | 6.97 |
Valuation Ratios
The PE ratio is -3.31 and the forward PE ratio is -20.78.
| PE Ratio | -3.31 |
| Forward PE | -20.78 |
| PS Ratio | 789.12 |
| Forward PS | 24.3 |
| PB Ratio | 0.87 |
| P/FCF Ratio | -3.52 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for CG Oncology Inc. Common stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.62, with a Debt / Equity ratio of 0.
| Current Ratio | 13.62 |
| Quick Ratio | 13.62 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.26% and return on capital (ROIC) is -29.93%.
| Return on Equity (ROE) | -0.26% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -29.93% |
| Revenue Per Employee | 3.34K |
| Profits Per Employee | -796.84K |
| Employee Count | 61 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so CG Oncology Common stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 33.38 |
| 200-Day Moving Average | 34.82 |
| Relative Strength Index (RSI) | 48.54 |
| Average Volume (20 Days) | 613.84K |
Income Statement
In the last 12 months, CG Oncology Common stock had revenue of 204.00K and earned -48.61M in profits. Earnings per share was -15.65.
| Revenue | 204.00K |
| Gross Profit | 204.00K |
| Operating Income | -55.45M |
| Net Income | -48.61M |
| EBITDA | -55.43M |
| EBIT | -55.45M |
| Earnings Per Share (EPS) | -15.65 |
Balance Sheet
The company has 8.27M in cash and 461.00K in debt, giving a net cash position of 7.80M.
| Cash & Cash Equivalents | 8.27M |
| Total Debt | 461.00K |
| Net Cash | 7.80M |
| Retained Earnings | -129.94M |
| Total Assets | 552.47M |
| Working Capital | 536.45M |
Cash Flow
In the last 12 months, operating cash flow was -45.68M and capital expenditures 0, giving a free cash flow of -45.68M.
| Operating Cash Flow | -45.68M |
| Capital Expenditures | 0 |
| Free Cash Flow | -45.68M |
| FCF Per Share | -10.55 |
Margins
Gross margin is 10.00K%, with operating and profit margins of -2.72M% and -2.38M%.
| Gross Margin | 10.00K% |
| Operating Margin | -2.72M% |
| Pretax Margin | -2.38M% |
| Profit Margin | -2.38M% |
| EBITDA Margin | -27.17K% |
| EBIT Margin | -27.18K% |
| FCF Margin | -22.39K% |
Dividends & Yields
CGON does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -51.31% |
| FCF Yield | -1.97% |
Analyst Forecast
The average price target for CGON is $65, which is 113.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $65 |
| Price Target Difference | 113.1% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 82.46 |
| Piotroski F-Score | 2 |